{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:03:30Z","timestamp":1789340610459,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":100,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10433-3","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:37:21Z","timestamp":1780720641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["cPLA2\u03b1 inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment"],"prefix":"10.1038","volume":"9","author":[{"given":"Ran","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huien","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengwei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aomei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9964-7570","authenticated-orcid":false,"given":"Zhiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-1080","authenticated-orcid":false,"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-8005","authenticated-orcid":false,"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"10433_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks, L. E. L. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Prim. 10, 71 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10433_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer, M. L. et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404, 803\u2013822 (2024).","journal-title":"Lancet"},{"key":"10433_CR3","doi-asserted-by":"crossref","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","DOI":"10.1200\/JCO.22.01989"},{"key":"10433_CR4","doi-asserted-by":"crossref","unstructured":"de Castro, G., Jr. et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u22651% in the KEYNOTE-042 study. J. Clin. Oncol. 41, 1986\u20131991 (2023).","DOI":"10.1200\/JCO.21.02885"},{"key":"10433_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer, J. D. et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 404, 1240\u20131252 (2024).","journal-title":"Lancet"},{"key":"10433_CR6","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N. Engl. J. Med. 389, 1672\u20131684 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10433_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng, W., Kang, K., Zhao, A. & Wu, Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J. Hematol. Oncol. 17, 54 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"10433_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","volume":"22","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nat. Rev. Clin. Oncol. 22, 200\u2013214 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10433_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi, G. R. et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun.44, 521\u2013553 (2024).","journal-title":"Cancer Commun."},{"key":"10433_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10433_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin, X. et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol. Cancer 23, 108 (2024).","journal-title":"Mol. Cancer"},{"key":"10433_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield, L. H. & Najjar, Y. G. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat. Rev. Immunol. 24, 399\u2013416 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"10433_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41419-024-06945-7","volume":"15","author":"N Li","year":"2024","unstructured":"Li, N. et al. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway. Cell Death Dis. 15, 555 (2024).","journal-title":"Cell Death Dis."},{"key":"10433_CR14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/ijms24021353","volume":"24","author":"SA Khan","year":"2023","unstructured":"Khan, S. A. & Ilies, M. A. The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles. Int. J. Mol. Sci. 24, 1353 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"10433_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.canlet.2017.06.022","volume":"403","author":"H Fu","year":"2017","unstructured":"Fu, H. et al. cPLA2\u03b1 activates PI3K\/AKT and inhibits Smad2\/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells. Cancer Lett. 403, 260\u2013270 (2017).","journal-title":"Cancer Lett."},{"key":"10433_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.152","volume":"8","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. cPLA2\u03b1 mediates TGF-\u03b2-induced epithelial-mesenchymal transition in breast cancer through PI3k\/Akt signaling. Cell Death Dis. 8, e2728 (2017).","journal-title":"Cell Death Dis."},{"key":"10433_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/stem.3157","volume":"38","author":"Y He","year":"2020","unstructured":"He, Y. et al. cPLA2\u03b1 reversibly regulates different subsets of cancer stem cells transformation in cervical cancer. Stem Cells 38, 487\u2013503 (2020).","journal-title":"Stem Cells"},{"key":"10433_CR18","doi-asserted-by":"crossref","unstructured":"Fang, X. et al. Xingxiao pills suppresses lung adenocarcinoma progression by modulating lipid metabolism and inhibiting the PLA2G4A-GLI1-SOX2 axis. Phytomedicine 143, 156826 (2025).","DOI":"10.1016\/j.phymed.2025.156826"},{"key":"10433_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06485-4","volume":"23","author":"Z Huang","year":"2025","unstructured":"Huang, Z. et al. scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer. J. Transl. Med. 23, 478 (2025).","journal-title":"J. Transl. Med."},{"key":"10433_CR20","doi-asserted-by":"publisher","first-page":"e148028","DOI":"10.1172\/jci.insight.148028","volume":"6","author":"Y Zhan","year":"2021","unstructured":"Zhan, Y. et al. PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+\u03b3\u03b4 Treg polarization. JCI Insight 6, e148028 (2021).","journal-title":"JCI Insight"},{"key":"10433_CR21","doi-asserted-by":"crossref","unstructured":"Mishra, S. et al. cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment. J. Exp. Clin. Cancer Res. 41, 54 (2022).","DOI":"10.1186\/s13046-021-02221-0"},{"key":"10433_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010403","volume":"13","author":"Y Xu","year":"2025","unstructured":"Xu, Y. et al. Lipid metabolic remodeling delays senescence of T cells to potentiate their immunity against solid tumors. J. Immunother. Cancer 13, e010403 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"10433_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41586-024-08257-4","volume":"637","author":"A Elewaut","year":"2025","unstructured":"Elewaut, A. et al. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature 637, 716\u2013725 (2025).","journal-title":"Nature"},{"key":"10433_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41590-024-01792-2","volume":"25","author":"JH Chen","year":"2024","unstructured":"Chen, J. H. et al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat. Immunol. 25, 644\u2013658 (2024).","journal-title":"Nat. Immunol."},{"key":"10433_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai, S., Itahashi, K. & Nishikawa, H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat. Rev. Clin. Oncol. 21, 337\u2013353 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10433_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2952","volume":"16","author":"SY Neo","year":"2024","unstructured":"Neo, S. Y. et al. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6\/STAT3 axis. Sci. Transl. Med. 16, eadi2952 (2024).","journal-title":"Sci. Transl. Med."},{"key":"10433_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell 37, 324\u2013339.e328 (2020).","journal-title":"Cancer Cell"},{"key":"10433_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00280-021-04322-1","volume":"88","author":"Y Liao","year":"2021","unstructured":"Liao, Y., Chen, W., Shi, W. & Zha, H. Targeting cPLA2\u03b1 inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras\/MEK\/ERK and Akt\/\u03b2-catenin pathways. Cancer Chemother. Pharmacol. 88, 689\u2013697 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10433_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ebiom.2019.08.062","volume":"47","author":"R Sun","year":"2019","unstructured":"Sun, R. et al. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A\/PGE2\/STAT3 pathway. EBioMedicine 47, 142\u2013155 (2019).","journal-title":"EBioMedicine"},{"key":"10433_CR30","doi-asserted-by":"publisher","first-page":"113361","DOI":"10.1016\/j.intimp.2024.113361","volume":"143","author":"D Liu","year":"2024","unstructured":"Liu, D., Liu, L., Li, H., Huang, Z. & Wang, Y. Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K\/AKT\/PD-L1 axis. Int. Immunopharmacol. 143, 113361 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"10433_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1136\/gutjnl-2023-331773","volume":"73","author":"H He","year":"2024","unstructured":"He, H. et al. Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer. Gut 73, 1529\u20131542 (2024).","journal-title":"Gut"},{"key":"10433_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217470","volume":"612","author":"L Yang","year":"2025","unstructured":"Yang, L. et al. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation. Cancer Lett. 612, 217470 (2025).","journal-title":"Cancer Lett."},{"key":"10433_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/0008-5472.CAN-24-0954","volume":"85","author":"P Xie","year":"2025","unstructured":"Xie, P. et al. ACE2 enhances sensitivity to PD-L1 blockade by inhibiting macrophage-induced immunosuppression and angiogenesis. Cancer Res. 85, 299\u2013313 (2025).","journal-title":"Cancer Res."},{"key":"10433_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010612","volume":"13","author":"H Jeong","year":"2025","unstructured":"Jeong, H. et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer. J. Immunother. Cancer 13, e010612 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"10433_CR35","doi-asserted-by":"crossref","unstructured":"Hu, Y., Dong, Z. & Liu, K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J. Exp. Clin. Cancer Res. 43, 23 (2024).","DOI":"10.1186\/s13046-024-02949-5"},{"key":"10433_CR36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/070674378503000412","volume":"30","author":"M Silberfeld","year":"1985","unstructured":"Silberfeld, M., Streiner, B. & Ciampi, A. Suicide attempters, ideators and risk-taking propensity. Can. J. Psychiatry Rev. 30, 274\u2013277 (1985).","journal-title":"Can. J. Psychiatry Rev."},{"key":"10433_CR37","doi-asserted-by":"publisher","first-page":"117382","DOI":"10.1016\/j.bmc.2023.117382","volume":"91","author":"X Yang","year":"2023","unstructured":"Yang, X., Xu, L., Yang, L. & Xu, S. Research progress of STAT3-based dual inhibitors for cancer therapy. Bioorg. Med. Chem. 91, 117382 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"10433_CR38","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/cac2.12591","volume":"44","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment. Cancer Commun. 44, 929\u2013966 (2024).","journal-title":"Cancer Commun."},{"key":"10433_CR39","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.7150\/ijbs.99716","volume":"20","author":"L Li","year":"2024","unstructured":"Li, L. et al. Tumor ABCC4-mediated release of PGE2 induces CD8(+) T cell dysfunction and impairs PD-1 blockade in prostate cancer. Int. J. Biol. Sci. 20, 4424\u20134437 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"10433_CR40","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-23-2627","volume":"84","author":"J Boumelha","year":"2024","unstructured":"Boumelha, J. et al. CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Cancer Res. 84, 2231\u20132246 (2024).","journal-title":"Cancer Res."},{"key":"10433_CR41","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257\u20131270 (2015).","journal-title":"Cell"},{"key":"10433_CR42","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/biom13121803","volume":"13","author":"M Mosca","year":"2023","unstructured":"Mosca, M., Nigro, M. C., Pagani, R., De Giglio, A. & Di Federico, A. Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond. Biomolecules 13, 1803 (2023).","journal-title":"Biomolecules"},{"key":"10433_CR43","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1111\/cas.15964","volume":"114","author":"Q Huai","year":"2023","unstructured":"Huai, Q. et al. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy. Cancer Sci. 114, 4484\u20134498 (2023).","journal-title":"Cancer Sci."},{"key":"10433_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310318","volume":"36","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Engineering and targeting neutrophils for cancer therapy. Adv. Mater. 36, e2310318 (2024).","journal-title":"Adv. Mater."},{"key":"10433_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02004-z","volume":"23","author":"X Huang","year":"2024","unstructured":"Huang, X. et al. Neutrophils in Cancer immunotherapy: friends or foes? Mol. Cancer 23, 107 (2024).","journal-title":"Mol. Cancer"},{"key":"10433_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202937","volume":"10","author":"N Niu","year":"2023","unstructured":"Niu, N. et al. Tumor cell-intrinsic SETD2 deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis. Adv. Sci. 10, e2202937 (2023).","journal-title":"Adv. Sci."},{"key":"10433_CR47","doi-asserted-by":"crossref","unstructured":"Sun, D. et al. CXCL5 impedes CD8(+) T cell immunity by upregulating PD-L1 expression in lung cancer via PXN\/AKT signaling phosphorylation and neutrophil chemotaxis. J. Exp. Clin. Cancer Res. CR 43, 202 (2024).","DOI":"10.1186\/s13046-024-03122-8"},{"key":"10433_CR48","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41423-024-01216-z","volume":"21","author":"A Mantovani","year":"2024","unstructured":"Mantovani, A., Marchesi, F., Di Mitri, D. & Garlanda, C. Macrophage diversity in cancer dissemination and metastasis. Cell. Mol. Immunol. 21, 1201\u20131214 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"10433_CR49","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas, M. J. et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42, 1032\u20131050.e1010 (2024).","journal-title":"Cancer Cell"},{"key":"10433_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo, B. et al. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J. Hematol. Oncol. 17, 44 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"10433_CR51","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai, J. et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun. 44, 1231\u20131260 (2024).","journal-title":"Cancer Commun."},{"key":"10433_CR52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jare.2025.02.034","volume":"78","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y. et al. NRIR promotes immune escape in hepatocellular cancer by regulating IFN\u03b3-induced PD-L1 expression. J. Adv. Res. 78, 423\u2013434 (2025).","journal-title":"J. Adv. Res."},{"key":"10433_CR53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2016.12.031","volume":"389","author":"D Tong","year":"2017","unstructured":"Tong, D. et al. Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2\/PGE2\/STAT3 axis. Cancer Lett. 389, 23\u201332 (2017).","journal-title":"Cancer Lett."},{"key":"10433_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","volume":"6","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct. Target. Ther. 6, 94 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10433_CR55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13543776.2017.1246540","volume":"27","author":"MG Kokotou","year":"2017","unstructured":"Kokotou, M. G., Limnios, D., Nikolaou, A., Psarra, A. & Kokotos, G. Inhibitors of phospholipase A(2) and their therapeutic potential: an update on patents (2012-2016). Expert Opin. Ther. Pat. 27, 217\u2013225 (2017).","journal-title":"Expert Opin. Ther. Pat."},{"key":"10433_CR56","doi-asserted-by":"crossref","unstructured":"Nikolaou, A., Kokotou, M. G., Vasilakaki, S. & Kokotos, G. Corrigendum to \u201cSmall-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2\u201d [Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864\/6 2019 941-956]. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864, 1681 (2019).","DOI":"10.1016\/j.bbalip.2018.08.009"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10433-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:20:01Z","timestamp":1789338001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10433"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10433-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1194"}}